An interleukin-6 (IL-6) receptor polymorphism affe...[Am J Gastroenterol. 2008] - PubMed Result

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Am J Gastroenterol. 2008 Apr;103(4):1045; author reply 1045-6. Links

Comment on:: Am J Gastroenterol. 2007 Oct;102(10):2164-70.

An interleukin-6 (IL-6) receptor polymorphism affecting serum levels of IL-6 does not increase the risk of cholangiocarcinoma in primary sclerosing cholangitis.

Melum E, Karlsen TH, Bergquist A, Schrumpf E, Boberg KM.

PMID: 18397431 [PubMed - indexed for MEDLINE]

Related articles

CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation.
Liver Transpl Surg. 1995 Mar; 1(2):94-8.

[Liver Transpl Surg. 1995]
Targeting IL-6 in cholangiocarcinoma therapy.
Am J Gastroenterol. 2007 Oct; 102(10):2171-2.

[Am J Gastroenterol. 2007]
Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis.
Hepatology. 2008 Jan; 47(1):8-10.

[Hepatology. 2008]
ReviewGenetic epidemiology of primary sclerosing cholangitis.
World J Gastroenterol. 2007 Nov 7; 13(41):5421-31.

[World J Gastroenterol. 2007]
ReviewDiagnosis of cholangiocarcinoma in patients with PSC: a sight on cytology.
J Hepatol. 2006 Oct; 45(4):476-9. Epub 2006 Jul 25.

[J Hepatol. 2006]
» See reviews... | » See all...

Recent Activity

Clear Turn Off Turn On

An interleukin-6 (IL-6) receptor polymorphism affecting serum levels of IL-6 does not incr...An interleukin-6 (IL-6) receptor polymorphism affecting serum levels of IL-6 does not increase the risk of cholangiocarcinoma in primary sclerosing cholangitis.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show